{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:31:10Z","timestamp":1793338270286,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.10.009","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:01Z","timestamp":1791588361000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Five decades of gene therapy innovation and regulation in the US and EU: A historical analysis"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8464-8526","authenticated-orcid":false,"given":"Thomas Wessel","family":"van de Voort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2817-1229","authenticated-orcid":false,"given":"Jarno","family":"Hoekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9724-5308","authenticated-orcid":false,"given":"Elisabeth Henrica Maria","family":"Moors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0014-8625","authenticated-orcid":false,"given":"Lourens Theo","family":"Bloem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.10.009_bib1","volume":"242","year":"2009","journal-title":"Eurpoean union"},{"key":"10.1016\/j.ymthe.2026.10.009_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12687-020-00480-6","article-title":"Curative gene therapies for rare diseases","volume":"12","author":"Maldonado","year":"2021","journal-title":"J. Community Genet."},{"key":"10.1016\/j.ymthe.2026.10.009_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.drudis.2020.11.024","article-title":"Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions","volume":"26","author":"van Overbeeke","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.10.009_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrd3052","article-title":"Challenges with advanced therapy medicinal products and how to meet them","volume":"9","author":"Schneider","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.10.009_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.stem.2016.08.012","article-title":"Overcoming Challenges Facing Advanced Therapies in the EU Market","volume":"19","author":"Abou-El-Enein","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.10.009_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.stem.2017.09.007","article-title":"Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment","volume":"21","author":"Abou-El-Enein","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.10.009_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/rego.12496","article-title":"Is regulatory innovation fit for purpose? A case study of adaptive regulation for advanced biotherapeutics","volume":"17","author":"De Grandis","year":"2023","journal-title":"Regul. Gov."},{"key":"10.1016\/j.ymthe.2026.10.009_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11024-017-9326-0","article-title":"Stretching and Challenging the Boundaries of Law: Varieties of Knowledge in Biotechnologies Regulation","volume":"55","author":"Faulkner","year":"2017","journal-title":"Minerva"},{"key":"10.1016\/j.ymthe.2026.10.009_bib9","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41591-022-01934-9","article-title":"Ensuring a future for gene therapy for rare diseases","volume":"28","author":"Aiuti","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104337","article-title":"Long-term follow-up after authorization of gene therapy: leveraging real-world data","volume":"30","author":"de Haart","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.10.009_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12916-017-0818-4","article-title":"Innovative regenerative medicines in the EU: a better future in evidence?","volume":"15","author":"Corbett","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib12","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.stem.2023.07.004","article-title":"Regulation of advanced therapies in Europe: Are we on the right track?","volume":"30","author":"Izeta","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.10.009_bib13","series-title":"ROCTAVIAN","year":"2026"},{"key":"10.1016\/j.ymthe.2026.10.009_bib14","article-title":"Pfizer Jettisons FDA-Approved Hemophilia B Gene Therapy Beqvez","author":"Stansfield","year":"2026","journal-title":"CGTlive\u00ae"},{"key":"10.1016\/j.ymthe.2026.10.009_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/312393a0","article-title":"Gene therapy: US clinical trials imminent","volume":"312","author":"Budiansky","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2026.10.009_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/d41573-019-00180-y","article-title":"How many rare diseases are there?","volume":"19","author":"Haendel","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.10.009_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrd3493","article-title":"Accelerating access to treatments for rare diseases","volume":"10","author":"Dunoyer","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.10.009_bib18","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41587-025-02744-3","article-title":"Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable","volume":"43","author":"Kassim","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.10.009_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2025.118794","article-title":"Promises past and future - Gene therapy and the actualisation of future expectations","volume":"389","author":"Hilberg","year":"2026","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib20","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1016\/j.ymthe.2025.09.049","article-title":"Overcoming barriers to commercially pre-viable gene and cell therapies for rare and ultra-rare diseases","volume":"33","author":"Barrett","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib21","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13023-024-03249-z","article-title":"Challenges for gene therapy in the financial sustainability of health systems: a scoping review","volume":"19","author":"Ossandon","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2026.10.009_bib22","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/mt.2013.157","article-title":"Pathway for Approval of a Gene Therapy Orphan Product: Treading New Ground","volume":"21","author":"Byrne","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.10.009_bib24","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41431-018-0309-x","article-title":"Moving towards a cure in genetics: what is needed to bring somatic gene therapy to the clinic?","volume":"27","author":"Cornel","year":"2019","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.10.009_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.18609\/cgti.2019.156","article-title":"Post-marketing safety and efficacy surveillance of cell and gene therapies in the EU: A critical review","volume":"5","author":"Fritsche","year":"2019","journal-title":"Cell Gene Ther. Insights"},{"key":"10.1016\/j.ymthe.2026.10.009_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.855100","article-title":"A Regulatory Risk-Based Approach to ATMP\/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations","volume":"9","author":"Salazar-Fontana","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpt.894","article-title":"Global Regulatory Differences for Gene- and Cell-Based Therapies: Consequences and Implications for Patient Access and Therapeutic Innovation","volume":"103","author":"Coppens","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib28","series-title":"The Government of Risk: Understanding Risk Regulation Regimes","author":"Hood","year":"2001"},{"key":"10.1016\/j.ymthe.2026.10.009_bib29","series-title":"Regulating Next Generation Agri-Food Biotechnologies","article-title":"Regulatory lifecycles and comparative biotechnology regulation: Analysing regulatory regimes in space and time","author":"Howlett","year":"2012"},{"key":"10.1016\/j.ymthe.2026.10.009_bib30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.respol.2009.01.017","article-title":"Regulatory policy as innovation: Constructing rules of engagement for a technological zone of tissue engineering in the European Union","volume":"38","author":"Faulkner","year":"2009","journal-title":"Res. Policy"},{"key":"10.1016\/j.ymthe.2026.10.009_bib31","series-title":"Understanding Regulation: Theory, Strategy, and Practice","author":"Baldwin","year":"2011"},{"key":"10.1016\/j.ymthe.2026.10.009_bib32","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/j.clinthera.2021.02.006","article-title":"Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future","volume":"43","author":"Pimenta","year":"2021","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcyt.2018.03.038","article-title":"A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making","volume":"20","author":"Coppens","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.10.009_bib34","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nbt0617-491","article-title":"After Glybera\u2019s withdrawal, what\u2019s next for gene therapy?","volume":"35","author":"Senior","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2026.10.009_bib35","series-title":"The Politics of Precaution","article-title":"The Politics of Precaution: Regulating Health, Safety, and Environmental Risks in Europe and the United States","author":"Vogel","year":"2012"},{"key":"10.1016\/j.ymthe.2026.10.009_bib36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/1535676019854866","article-title":"The United States\u2019 Regulatory Environment Is Evolving to Accommodate a Coming Boom in Gene Therapy Research","volume":"24","author":"Eisenman","year":"2019","journal-title":"Appl. Biosaf."},{"key":"10.1016\/j.ymthe.2026.10.009_bib37","series-title":"Regulatory Innovation: A Comparative Analysis","author":"Black","year":"2006"},{"key":"10.1016\/j.ymthe.2026.10.009_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2026.10.009_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ng1092-93","article-title":"A brief history of gene therapy","volume":"2","author":"Friedmann","year":"1992","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2026.10.009_bib40","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/humc.2013.087","article-title":"Lessons learned from the clinical development and market authorization of Glybera","volume":"24","author":"Bryant","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.10.009_bib41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ijpharm.2015.08.029","article-title":"Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR\/Cas9","volume":"494","author":"LaFountaine","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ymthe.2026.10.009_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/hum.1998.9.1-87","article-title":"The Commercial Development of Gene Therapy in Europe and the USA","volume":"9","author":"Martin","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib43","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1038\/s41591-024-03242-w","article-title":"The role of FDA advisory committees","volume":"30","author":"Helms Williams","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib44","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1089\/blr.1985.4.176","article-title":"Points To Consider In The Design And Submission Of Human Somatic-Cell Gene Therapy Protocols","volume":"4","year":"1985","journal-title":"Biotechnol. L. Rep"},{"key":"10.1016\/j.ymthe.2026.10.009_bib45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000524392","article-title":"Advanced Therapy Medicinal Products and the Changing Role of Academia","volume":"49","author":"Priesner","year":"2022","journal-title":"Transfus. Med. Hemother."},{"key":"10.1016\/j.ymthe.2026.10.009_bib46","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/bcp.70596","article-title":"Advanced therapy medicinal products (ATMPs) \u2013 An analysis of the global regulatory status","volume":"92","author":"Cramer","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymthe.2026.10.009_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17410541.2025.2515002","article-title":"Regional disparities in access to gene therapies in the European Union, the United States, Japan, and China","volume":"22","author":"Mohan","year":"2025","journal-title":"Per. Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib48","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.drudis.2014.07.011","article-title":"Channeling postmarketing patient data into pharmaceutical regulatory systems","volume":"19","author":"Barbosa","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2026.10.009_bib49","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.omtm.2021.04.001","article-title":"Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs","volume":"21","author":"Drago","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.10.009_bib50","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41392-025-02267-y","article-title":"Current landscape of innovative drug development and regulatory support in China","volume":"10","author":"Tan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/hum.2021.126","article-title":"An Overview of Cell and Gene Therapy Development in China","volume":"33","author":"Wang","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41434-020-0163-7","article-title":"An overview of development in gene therapeutics in China","volume":"27","author":"Wang","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145889","article-title":"Human gene therapy: A patent analysis","volume":"803","author":"Zhou","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.ymthe.2026.10.009_bib54","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cpt.70099","article-title":"Cell and Gene Therapy Product Approvals in China: Insights into Clinical Trials and Regulatory Advances","volume":"118","author":"Huang","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib55","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1016\/j.ymthe.2023.11.001","article-title":"The state of cell and gene therapy in 2023","volume":"31","author":"Chancellor","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib56","article-title":"Cell and gene therapy regulatory, pricing, and reimbursement framework: With a focus on South Korea and the EU","volume":"11","author":"Lee","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.ymthe.2026.10.009_bib57","doi-asserted-by":"crossref","first-page":"29321","DOI":"10.3402\/jmahp.v3.29321","article-title":"Reimbursement of licensed cell and gene therapies across the major European healthcare markets","volume":"3","author":"J\u00f8rgensen","year":"2015","journal-title":"J. Mark. Access Health Policy"},{"key":"10.1016\/j.ymthe.2026.10.009_bib58","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jcyt.2024.02.017","article-title":"Cell and gene therapy investment: evolution and future outlook on investor perspectives","volume":"26","author":"Kunze-K\u00fcllmer","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ymthe.2026.10.009_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41392-024-01770-y","article-title":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib60","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/d41573-024-00120-5","article-title":"Chinese innovative drug R&D trends in 2024","volume":"23","author":"Chen","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2026.10.009_bib61","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/10430342261437961","article-title":"FDA Issues Plausible Mechanism Pathway Draft Guidance","volume":"37","author":"Philippidis","year":"2026","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.10.009_bib62","unstructured":"Purple Book Search. Accessed June 5, 2026. https:\/\/purplebooksearch.fda.gov\/."},{"key":"10.1016\/j.ymthe.2026.10.009_bib63","series-title":"CBER-regulated Products with Supporting Documents","year":"2026"},{"key":"10.1016\/j.ymthe.2026.10.009_bib64","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymthe.2026.10.009_bib65","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s42256-020-00287-7","article-title":"An open source machine learning framework for efficient and transparent systematic reviews","volume":"3","author":"van de Schoot","year":"2021","journal-title":"Nat. Mach. Intell."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:44:59Z","timestamp":1793335499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626008671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":65,"alternative-id":["S1525001626008671"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.10.009","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five decades of gene therapy innovation and regulation in the US and EU: A historical analysis","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}